CX 04328
CAS No. 957890-42-5
CX 04328( LEDGIN-6 )
Catalog No. M16841 CAS No. 957890-42-5
CX 04328 (LEDGIN-6) is an allosteric HIV-1 integrase inhibitor that inhibits the LEDGF/p75-integrase interaction with IC50 of 1.37 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 262 | In Stock |
|
| 50MG | 1188 | In Stock |
|
| 100MG | 1791 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCX 04328
-
NoteResearch use only, not for human use.
-
Brief DescriptionCX 04328 (LEDGIN-6) is an allosteric HIV-1 integrase inhibitor that inhibits the LEDGF/p75-integrase interaction with IC50 of 1.37 uM.
-
DescriptionCX 04328 (LEDGIN-6) is an allosteric HIV-1 integrase inhibitor that inhibits the LEDGF/p75-integrase interaction with IC50 of 1.37 uM, antiviral activity EC50 of 2.35 uM.
-
In Vitro——
-
In Vivo——
-
SynonymsLEDGIN-6
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research AreaInfection
-
Indication——
Chemical Information
-
CAS Number957890-42-5
-
Formula Weight353.846
-
Molecular FormulaC21H20ClNO2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL 282.61 mM; H2O : < 0.1 mg/mL
-
SMILESCCCC(C1=C(C2=CC=CC=C2)C3=CC(Cl)=CC=C3N=C1C)C(O)=O
-
Chemical Name2-(6-chloro-2-methyl-4-phenylquinolin-3-yl)pentanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Christ F, et al. Nat Chem Biol. 2010 Jun;6(6):442-8.
molnova catalog
related products
-
Dolutegravir
Dolutegravir (GSK1349572) is a potent, next-generation HIV integrase (IN) inhibitor, inhibits HIV-1 integrase-catalyzed strand transfer with IC50 of 2.7 nM.
-
YIR-821
YIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM).
-
BNM-III-170 trifluor...
BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.
Cart
sales@molnova.com